Why GC Biopharma’s ALYGLO research push could matter more than another conference poster
IVIG differentiation is getting technical. GC Biopharma’s ALYGLO push shows why molecular trust may shape the next adoption battle.
Pharma & Biotech
Pharma & Biotech
Why SV Health Investors’ EpiVax acquisition signals a bigger private equity push into immunogenicity services
SV Health Investors acquires EpiVax. Read why immunogenicity risk assessment is becoming a more strategic pharma services market.